Tg Therapeutics TGTX
NASDAQ TGTX
$55.78 -0.41 (-0.73%)
At close: Sep 30, 2026 · 4:00 PM EDT

Tg Therapeutics (TGTX) EV to EBIT (2023 - 2026)

Updated

Tg Therapeutics' (TGTX) EV to EBIT was 57.20 for Q2 2026, down 9.2% from 63.00 a year earlier but up 89.5% from the prior quarter.

Analysis

Tg Therapeutics (TGTX) EV to EBIT (2023 - 2026) Analysis & Trends

For FY2025, EV to EBIT at Tg Therapeutics was 35.92, down 65.6% from FY2024.

  • By year, EV to EBIT came in at 104.45 in FY2024 (-9.0%) and 114.81 in FY2023.
  • Five-year quarterly EV to EBIT spans a low of 24.91 in Q2 2024 and a high of 114.81 in Q4 2023.
  • Year over year, EV to EBIT has now declined in each of the last three quarters, with growth averaging 20.7% over the last six quarters.
  • Per Business Quant data, the three quarters before Q2 2026 came in at 30.19 (Q1 2026), 35.92 (Q4 2025) and 52.81 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Tg Therapeutics 8.54 Bn 7.93 Bn 199.14 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 57.20
Mar 31, 2026 30.19
Dec 31, 2025 35.92
Sep 30, 2025 52.81
Jun 30, 2025 63.00
Mar 31, 2025 99.64
Dec 31, 2024 104.45
Jun 30, 2024 24.91
Mar 31, 2024 44.28
Dec 31, 2023 114.81
API Access

Tg Therapeutics EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=TGTX&period=max&api_key=YOUR_API_KEY